CMRX250117P6000
- 3.05
- 0.000.00%
Chimerix Newsroom
Top-rated Smaller Defensive Stocks After Societe Generale Permabear Takes Contrarian View
Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?
H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
Express News | HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans
CervoMed CRVO Phase 2b Fails; Chimerix SNDA Application
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
Top Midday Gainers
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings
Chimerix Price Target Raised to $7 From $5 at JonesResearch
Chimerix CMRX NDA Plans; UniQure QURE Accelerated Approval Path
Dow Falls 150 Points; Oracle Posts Downbeat Results
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
Wall Street Set to Open Flat Tuesday as Investors Await Inflation Data
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
Investors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's Premarket
TD Cowen Reaffirms Their Buy Rating on Chimerix (CMRX)